Lipocine (LPCN) Receives a Buy from H.C. Wainwright
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Lipocine (LPCN), with a price target of $3.00. The company’s shares closed last Wednesday at $1.32.
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 6.8% and a 48.9% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Satsuma Pharmaceuticals, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lipocine with a $3.00 average price target.
See today’s analyst top recommended stocks >>
Lipocine’s market cap is currently $86.71M and has a P/E ratio of -3.80. The company has a Price to Book ratio of 7.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.